Relamorelin
Overview
Relamorelin is a synthetic pentapeptide ghrelin receptor agonist designed to stimulate growth hormone secretion and promote gastric motility. It binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a), mimicking the action of endogenous ghrelin.
Mechanism of Action
The peptide was developed primarily for the treatment of diabetic gastroparesis and other disorders of gastric emptying, with potential applications in cachexia and functional dyspepsia.
Research Summary & Key Findings
Phase 2 trials in diabetic gastroparesis demonstrated improvements in gastric emptying and symptom reduction, with data presented at Digestive Disease Week in 2017. Despite initial promise, development was discontinued by the sponsor in 2020. Clinical evidence supports prokinetic activity, though no regulatory approval has been obtained.
Clinical Status
Relamorelin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed — "Relamorelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Relamorelin"
Registered interventional and observational studies, including status and phase.
- PubChem — "Relamorelin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hormone
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...
View detailsIpamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...
View detailsSermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...
View detailsTesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...
View detailsStart Your Consultation
Get an AI-proposed Relamorelin protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Relamorelin.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.